Hydroxyurea

Quick links to important sections

Hydroxyurea

Selected form

Method of action: Antitumour, Cytostatic

Treatment option: Leukemia, Cancer, Thrombocythemia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hydroxyurea

Quick Facts

Property Description
Active ingredient Hydroxycarbamide (INN)
Form Capsule (Oral Formulation)
Pharmacological class Antineoplastic agent, Antimetabolite
General purpose Cell growth control (Cytoreduction)
Origin Synthetic compound

What Type of Medicine is Hydroxyurea (Hydroxycarbamide)?

Hydroxyurea, formally known by its International Nonproprietary Name (INN), Hydroxycarbamide, is a powerful synthetic compound classified as an antineoplastic agent and an antimetabolite. It functions as a cytotoxic agent used in the management of specific hematologic and oncologic conditions. The medicine is a prescription-only medication that falls into the broader category of oral chemotherapy.

Its specific action classifies Hydroxycarbamide as a Ribonucleotide Reductase Inhibitor, a mechanism distinct from many older forms of chemotherapy. This classification confirms that it is a medicine used to control or inhibit the growth of abnormal cells. The World Health Organization includes Hydroxyurea on its Model List of Essential Medicines, recognizing its importance in treating core health needs.


Composition and Pharmaceutical Form

Hydroxyurea is produced as a single-ingredient product, containing only Hydroxycarbamide as its sole active pharmaceutical ingredient. It is most commonly dispensed as an opaque capsule, taken via the oral route of administration.

While the drug is marketed under various trade names, all contain the identical active substance, Hydroxycarbamide. The oral capsule form ensures systemic treatment, allowing the active compound to be absorbed through the digestive system to affect cells throughout the body. The product is not a combination drug; all its therapeutic effects are attributed directly to the action of the parent molecule.


General Purpose and Effect on Cell Growth

The general therapeutic purpose of Hydroxyurea is to provide a cytoreductive effect by controlling the proliferation of cells. It achieves this by disrupting the process of DNA synthesis in rapidly dividing cells. This fundamental action helps manage conditions characterized by the excessive multiplication or abnormal activity of certain blood-forming cells.

As an antimetabolite, Hydroxycarbamide interferes with a critical enzyme required to build the blocks of new DNA, thereby regulating cell growth. Furthermore, the medicine possesses the unique property of inducing Fetal Hemoglobin (HbF), which is leveraged to improve the function of red blood cells in specific genetic disorders.

What side effects are possible with Hydroxyurea?

Possible side effects and safety information

The safety profile of Hydroxyurea (Hydroxycarbamide) is primarily defined by its effects as an antineoplastic agent. The most frequent and often dose-limiting adverse reaction is Myelosuppression (suppression of blood cell production), which is classified as Very Common in regulatory documents, including Leukopenia, Thrombocytopenia, and Anemia.

Adverse reactions are formally grouped by System-Organ-Classes, including Blood and Lymphatic System Disorders, Gastrointestinal Disorders (e.g., Stomatitis, Nausea), and Skin and Subcutaneous Tissue Disorders (e.g., Maculopapular rash, Hyperpigmentation).

Serious Adverse Reactions and Safety Constraints

Official labeling documents serious adverse reactions such as potentially fatal Interstitial Lung Disease and Pancreatitis. Furthermore, the drug is associated with Secondary Malignancies (skin cancer, leukemia), particularly with long-term therapy for myeloproliferative disorders. Other skin effects, including vasculitic toxicities and skin ulcers, are also associated with extended exposure.

Safety constraints exist for specific populations. The drug is contraindicated in individuals with pre-existing severe myelosuppression. Older adults may face an increased risk of myelosuppression and leg ulcers, and patients with renal impairment typically require potential dose adjustments due to the drug's primary route of excretion.

Frequency of Key Adverse Reactions

Classification Examples of Reactions
Very Common Myelosuppression, Leukopenia, Anemia, Stomatitis
Common Maculopapular rash, Fever, Alopecia
Rare Pulmonary reactions, Pancreatitis, Skin Ulcers

Overdose and Emergency Response

Hydroxyurea Overdose and when to seek help

Domain Official Regulatory Statement
Documented overdose presentations Acute and severe myelosuppression (leukopenia, thrombocytopenia, anemia), acute mucocutaneous toxicity (severe stomatitis, cutaneous erythema, edema, hyperpigmentation), and neurological effects (agitation, myoclonic jerks, seizures).
Physiological systems affected Hematologic system, Gastrointestinal/Integumentary system, and Central Nervous System.
Emergency-response statements Treatment is strictly symptomatic and supportive. Required actions include stabilizing the airway, administering intravenous fluids, and consulting a medical toxicologist or Poison Center.
When immediate medical help is required Seek immediate medical attention following any acute overexposure or ingestion of a dose greater than prescribed.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Potential for severe and life-threatening toxicity, particularly related to severe myelosuppression and respiratory depression.
Overdose-context constraints No specific antidote is known. Management is constrained to supportive procedures such as blood product transfusions and activated charcoal (if appropriate).

Resulting Overdose Structure

Official Overdose Statements:

  • Overdosage results primarily in severe myelosuppression, necessitating prolonged monitoring of blood counts.
  • Acute mucocutaneous toxicity, including severe stomatitis and skin changes, is a documented clinical manifestation of overdose.
  • Seek immediate medical attention following any acute overexposure.
  • Management is strictly symptomatic and supportive, as no specific antidote is known.
  • Emergency actions involve stabilizing the airway and contacting a medical toxicologist or Poison Center.

Connection to the overall overdose profile Government regulatory documents strictly define the Hydroxyurea overdose profile based on its capacity to cause severe hematologic toxicity and acute systemic manifestations. The regulatory framework requires that immediate medical attention must be sought, given the risk of life-threatening complications and the official statement that treatment is confined to symptomatic and supportive measures because no specific antidote is available.

Therapeutic Uses of Hydroxyurea

What Hydroxyurea Treats: Main Uses and Benefits

Hydroxyurea is commonly used in conditions characterized by periods of heightened symptoms within chronic hematologic domains. This includes Sickle Cell Disease (SCD), where it is applied in addressing symptoms related to physical discomfort (recurrent painful crises), and myeloproliferative neoplasms such as Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Chronic Myeloid Leukemia (CML). For these conditions, it is used for managing symptoms related to systemic imbalance that create noticeable physiological strain.

Hydroxyurea may also be part of symptomatic management for conditions presenting with systemic or localized discomfort, such as certain cancers of the head and neck, where it is commonly used in combination with other treatments.

It provides supportive relief that helps patients cope more steadily during episodes of heightened discomfort.

“Provides supportive relief that helps patients cope more steadily during episodes of heightened discomfort.”


Quick Fact: Relief for Key Symptom Domains
SCD Use is applied in addressing symptoms related to physical discomfort (painful vaso-occlusive crises).
MPN Use is used for managing symptoms related to systemic imbalance that create noticeable physiological strain.
General Benefit Contributes to easing the overall symptom load during periods of heightened symptoms.

Eligibility and Restrictions for Use

Hydroxyurea's eligibility is strictly defined by regulatory authorities based on a patient's physiological status, organ function, and age.

Contraindicated Populations

The medicine is contraindicated (must not be used) in patients with a known hypersensitivity to Hydroxyurea or with marked bone marrow depression (myelosuppression). This includes individuals presenting with severe leukopenia (low white blood cell counts), severe thrombocytopenia (low platelet counts), or severe anemia.

Population Group Eligibility Status Basis
Pregnant Individuals Contraindicated Potential for fetal harm.
Breastfeeding Individuals Not Recommended Excretion into human milk.

Age and Condition-Based Restrictions

Use is established for adults across all labeled indications. For pediatric patients, use is specifically approved for Sickle Cell Disease but may be restricted or not established for other conditions. Older adults are eligible but require careful monitoring and potential lower-dose regimens.

Patients with renal impairment (reduced kidney function) require a mandatory dose reduction to limit systemic exposure. Use must be discontinued in patients who develop cutaneous vasculitic ulcers or other severe vasculitic toxicities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hydroxyurea's interaction profile is primarily defined by pharmacodynamic reinforcement and specific combination restrictions documented by regulatory authorities. Certain combinations must be avoided due to the heightened risk of serious toxicity, and others carry an officially documented risk of additive effects.


Combinations and Toxicity Reinforcement

Co-administration with Live Virus Vaccines (e.g., Yellow Fever or Measles/Mumps/Rubella) must be avoided, as the drug’s immunosuppressive properties may potentiate virus replication. The specific triple combination of hydroxyurea with didanosine and stavudine should be avoided due to the officially documented risk of fatal hepatic events, including hepatotoxicity and hepatic failure.

Combining hydroxyurea with other myelosuppressive agents or radiotherapy carries an additive pharmacodynamic risk, increasing the likelihood of bone marrow depression. Use with other antiretroviral drugs is associated with an increased risk of severe adverse reactions, including pancreatitis and peripheral neuropathy. Patients with a history of, or currently receiving, interferon therapy have a documented increased risk of developing cutaneous vasculitic toxicities.


Procedural and Assay Notes

Hydroxyurea is documented to interfere with certain clinical laboratory assays, potentially leading to falsely elevated results for tests measuring uric acid, urea, and lactic acid. For patients with End-Stage Renal Disease undergoing hemodialysis, the medicine is subject to a procedural administration constraint, requiring that it be given only following the completion of hemodialysis.

Mechanism of Action

Hydroxyurea exerts its physiological effects through three distinct molecular and cellular pathways.

Enzyme Inhibition and Cytoreduction

It functions as an inhibitor of ribonucleotide reductase (RR), a critical enzyme that converts ribonucleotides into deoxyribonucleotides, the precursors for DNA synthesis. By scavenging the tyrosyl free radical at the enzyme's active site, this action selectively inhibits DNA replication. This mechanistic cascade restricts the proliferation of rapidly dividing cells, particularly in the bone marrow, leading to a reduction in cell-line counts.

Fetal Hemoglobin Induction

The compound modulates pathways associated with hematopoiesis to increase the synthesis of fetal hemoglobin (HbF). This process is mediated, in part, by the generation of nitric oxide (NO), which activates a signaling sequence involving cyclic GMP. Elevated HbF levels modify the aggregation properties of HbS and modulate erythrocyte morphology and plasticity.

Vascular Wall Modulation

Hydroxyurea influences the adhesive properties of blood cells by reducing the expression of certain endothelial adhesion molecules. This effect modulates systemic physiological responses within the vasculature, leading to altered cellular adhesion properties.

Dosage and Administration Information

How to Use Hydroxyurea: Official Administration Guidelines

Hydroxyurea is administered via the oral route and must be used strictly according to the regimen prescribed by your healthcare provider. Its use is based on official instructions.


Administration Protocol

Parameter Instruction
Dosing Schedule The dose is typically weight-based, calculated using your actual or ideal body weight, and is adjusted over time based on specific blood count results.
Frequency For continuous treatment (e.g., Sickle Cell Disease), it is taken once daily at the same time each day.
Timing May be taken with or without food.

Form Handling and Precautions

Capsules must be swallowed whole. Do not crush, chew, or open the capsules, as the drug is considered a cytotoxic agent. If you are unable to swallow the capsule, certain tablet formulations may be dispersed in a small amount of water or the contents of opened capsules may be mixed with liquid and swallowed immediately, but this must only be done following explicit instructions from your provider.

Anyone handling the medication, particularly caregivers preparing a liquid dose, should wear disposable gloves to avoid direct skin contact. Hands must be washed before and after contact with the medication.

Dose Adjustments and Missed Doses

If you miss a dose, do not take a double dose to make up for it; contact your healthcare provider immediately for guidance. The dose must be adjusted or interrupted by the provider if blood cell counts fall below specified thresholds (myelosuppression). Patients with renal impairment (CrCl less than 60 mL/min) typically require a 50% dose reduction.

Recent Clinical Evidence

Research evidence / Overview of studies for Hydroxyurea


Evidence for use in Sickle Cell Disease (SCD)

Research for Sickle Cell Disease (SCD) was evaluated using various designs, including Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined outcomes related to the severe, episodic, and acute changes related to the condition. RCTs primarily measured outcomes related to physical discomfort, focusing on the frequency of painful vaso-occlusive crises (VOCs), along with rates of hospitalization and the need for blood transfusions. The studies included both adults and pediatric patients (children 2 years of age and older) who experience severe SCD manifestations.

Findings describe patterns where the frequency of VOCs was monitored in study populations and compared to control groups. Research highlights changes in measured Fetal Hemoglobin (HbF) levels and changes in other cell markers during the study period. Data show patterns related to rates of hospitalization and blood transfusion requirements that were monitored over the short to intermediate time intervals during which the research was conducted.

However, the existing studies provide limited information for the medicine's role in preventing long-term chronic organ damage, which is a primary concern in SCD. The research base also has limited data for patients who experience milder manifestations of the disease. Research has been ongoing, and long-term effects are not fully established for outcomes spanning multiple decades of continuous use.


Evidence for use in Myeloproliferative Neoplasms (MPN)

The research for Myeloproliferative Neoplasms (MPN), specifically Polycythemia Vera (PV) and Essential Thrombocythemia (ET), was studied through active comparator RCTs and large observational studies. Studies primarily monitored outcomes related to systemic imbalance by examining the ability to achieve Complete Hematologic Response, which is the normalization of red blood cell and platelet counts. Research also examined vascular outcomes, such as the incidence of thrombotic events (blood clots). These studies typically focused on adult patients identified as high-risk by the researchers based on their age or previous history of clotting.

Comparative trials and observational data reported measurements related to the defined endpoints for hematologic response in study participants. Evidence suggests findings related to thrombotic events that were monitored in study patients compared to cohorts not receiving the medicine. Research monitored the changes in molecular markers, such as the JAK2 V617F allele burden, but findings related to these markers were mixed and variable across studies.

Key Studies & References

  1. Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
  2. The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

Frequently Asked Questions (FAQ)

Common questions about Hydroxyurea (FAQ)

Q: Are there any long-term effects of taking Hydroxyurea for many years?

Official documents state that long-term use of hydroxyurea is associated with an increased risk of developing certain secondary cancers, including skin cancer and secondary leukemia. Other chronic effects, such as the formation of skin ulcers, are also noted with extended exposure. Patients may wish to discuss the long-term benefits and risks with their healthcare provider.

Q: Is it common to feel tired when starting Hydroxyurea?

Fatigue and unusual tiredness or weakness are listed in official product information as potential side effects. These symptoms may also be an indication of myelosuppression (low blood cell counts), which is a very common reaction that requires careful monitoring. If fatigue is severe or persistent, informing a healthcare provider is generally recommended.

Q: Is Hydroxyurea the same as Hydrea or Droxia?

Hydroxyurea is the active substance, which is the generic name for the medicine. It is available both as generic hydroxyurea capsules and under various brand names, including Hydrea and Droxia. All these products contain the identical active substance.

Q: If I am taking Hydroxyurea, can I still get routine vaccinations?

Official regulatory information indicates that the use of live virus vaccines (such as Measles, Mumps, and Rubella) should be avoided while taking this medication. This is because hydroxyurea has immunosuppressive properties that may increase the risk of severe infection from the vaccine.

Q: Can Hydroxyurea cause changes to my nails or skin color?

Yes, official safety information reports that the medicine can cause changes to the skin and nails. These reactions include darkening of the skin (hyperpigmentation), atrophy of the skin and nails, and the appearance of bluish-brownish bands on the nails.

Q: Does Hydroxyurea affect kidney function?

Official labeling notes that the medicine can cause elevations in blood urea nitrogen (BUN) and creatinine levels, which are markers of kidney function. Furthermore, because the medicine is primarily cleared by the kidneys, dose adjustments are typically necessary for patients who have pre-existing severe kidney impairment.

Q: Is Hydroxyurea considered a standard treatment for sickle cell disease?

Hydroxyurea (e.g., Droxia) is an FDA-approved medicine for patients with sickle cell anemia. Studies have examined its ability to reduce the frequency of painful crises and the need for blood transfusions, supporting its established role in therapy.

Q: What should be done if I accidentally get Hydroxyurea powder on my skin?

Due to its cytotoxic nature, if the powder from a capsule accidentally contacts the skin, the recommended instruction is to wash the area immediately and thoroughly with soap and water. Caregivers and patients are generally advised to wear disposable gloves when handling the medication.

Q: What happens if I take a double dose of Hydroxyurea by mistake?

Information on overdose describes potential severe reactions. Symptoms may include severe myelosuppression (effects on blood counts), severe sores in the mouth and throat, and swelling or scaling on the hands and feet. This is considered a serious medical event.

Q: What are the most common reasons why Hydroxyurea is prescribed in Europe?

According to the official European product information (SmPC), hydroxyurea is prescribed for specific hematologic conditions. These indications typically include Chronic Myeloid Leukemia, Polycythaemia Vera, Essential Thrombocythaemia, and in certain cases of Sickle Cell Syndrome.

Q: How quickly does Hydroxyurea start to work for my condition?

The official regulatory documents do not provide a specific timeframe for the onset of clinical benefit. Because the medicine works by making gradual changes to bone marrow function, it may take several weeks or even months of continuous therapy before benefits are observed.

Q: Can Hydroxyurea be stopped suddenly, or does it need to be tapered off?

The official labeling does not mandate a tapering-off schedule, but the medicine should not be discontinued without first consulting a healthcare provider. Discontinuation is typically managed under medical supervision.

Q: Can Hydroxyurea affect my ability to get pregnant or father a child?

Official information indicates that hydroxyurea can affect reproductive ability. It has been shown to cause infertility in males and may also have effects on the ovarian reserve in females. Regulatory documents indicate that males of reproductive potential may be advised to use effective contraception for at least one year after treatment.

Q: What foods or supplements should be avoided while taking Hydroxyurea?

The primary regulatory label does not list any specific interactions with common foods. While some general sources suggest avoiding alcohol, spicy, or acidic foods to manage potential gastrointestinal side effects, the official label does not mandate specific dietary restrictions.

Q: Does Hydroxyurea interact with common pain relievers like ibuprofen?

There is no direct, major interaction with common pain relievers like ibuprofen listed in the primary regulatory label. However, the label contains a general warning regarding the increased risk of bleeding when the medicine is combined with other drugs that affect blood cell production or function.

Q: Is it safe to drink alcohol while using Hydroxyurea?

The regulatory label does not list a direct chemical interaction with alcohol. Both alcohol use and hydroxyurea are associated with central nervous system effects such as headache and dizziness, and caution is generally advised.

Q: Can Hydroxyurea make skin more sensitive to the sun?

Official product information advises that the medicine can make the skin more sensitive to the sun. Because long-term use is associated with an increased risk of skin cancer, regulatory information advises avoiding unnecessary or prolonged sun exposure and using protective clothing and sunscreen.

Q: Are there any known interactions between Hydroxyurea and herbal supplements?

Regulatory documents generally advise that patients should tell their healthcare provider about all prescription and non-prescription medications, vitamins, nutritional supplements, and herbal products they are taking. No specific herbal product interaction is listed in the primary label.

Q: What should I do if I get sick while taking Hydroxyurea?

Since hydroxyurea can cause severe myelosuppression (low blood counts), it increases the risk of infection. Official patient instructions emphasize that symptoms such as fever, chills, sore throat, or other signs of infection may require immediate consultation with a healthcare provider.

Q: Is Hydroxyurea available as a generic medicine?

Yes, the medicine is available in a generic form. The active pharmaceutical ingredient is called hydroxyurea, and it is available both as generic hydroxyurea capsules and under various brand names.

Q: Can Hydroxyurea be taken with antacids or heartburn medicine?

The primary regulatory label does not list a direct interaction between hydroxyurea and common antacids. Consultation with a healthcare provider is generally recommended for all concurrent medications, including those for heartburn.

Q: How long after stopping Hydroxyurea do the effects wear off?

The decrease in blood cell counts caused by the medicine is generally rapidly reversible when the medicine is stopped. However, the official label notes that the effects on male fertility may persist for a longer period, potentially for at least one year.

Q: Are headaches a potential side effect of Hydroxyurea?

Yes. Headaches are listed in the official safety information as a potential adverse reaction of the medicine, classified under nervous system disorders.

Q: What does the package insert say about driving or operating machinery while on Hydroxyurea?

The regulatory label lists side effects such as drowsiness and dizziness. These effects could potentially impair a person's ability to drive or operate machinery.

Q: Why is folic acid sometimes taken along with Hydroxyurea?

Hydroxyurea can cause a change in red blood cell size called macrocytosis. While this is not related to a true folic acid deficiency, it is often recommended to discuss folic acid supplementation with a healthcare provider to manage this change.

Q: Can Hydroxyurea change liver enzyme levels?

Official safety information indicates that hepatotoxicity (liver damage) and elevations in liver enzyme levels have been reported. This effect is specifically noted in cases where hydroxyurea is used alongside certain antiretroviral drugs.

Q: Does Hydroxyurea cause issues with appetite or weight change?

Yes. Adverse reactions reported in official documents include loss of appetite (anorexia), nausea, and vomiting. Weight gain is also listed as a reported adverse reaction.

Q: Can Hydroxyurea interact with common vitamins like Vitamin C or D?

The regulatory label advises telling a doctor about all vitamins and supplements being taken. No specific interactions with common vitamins like Vitamin C or Vitamin D are listed in the primary label. The regulatory label generally notes the importance of informing a healthcare provider about all vitamins and supplements being taken.

How should Hydroxyurea be stored and disposed of?

Storage and Disposal of Hydroxyurea

Hydroxyurea is classified as a cytotoxic (hazardous) drug, requiring specific handling and disposal protocols as defined by regulatory documents (e.g., FDA, EMA, NIH).

Mandatory Storage and Stability

Condition Requirement
Temperature/Protection Store at controlled room temperature (typically leq 30 C), away from excess heat and moisture in the original, tightly closed container.
In-Use Stability Unused broken tablets, if applicable, must be replaced in the bottle and used within three months.

Handling and Disposal Requirements

Because the drug is cytotoxic, wear disposable gloves when handling the container or medication to prevent direct contact, and wash hands thoroughly afterward. Spilled powder must be wiped up immediately with a damp disposable towel and placed into a closed container. All unused medication and waste material must be disposed of according to local and national requirements for hazardous or anticancer products. The medication must be kept securely out of the reach of children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hydroxyurea found in:

A-Z Index: